184 related articles for article (PubMed ID: 33201)
1. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
[TBL] [Abstract][Full Text] [Related]
2. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
Bates TR; Blumenthal HP; Pieniaszek HJ
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
[TBL] [Abstract][Full Text] [Related]
3. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Bates TR; Blumenthal HP; Pieniaszek HJ
Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
[TBL] [Abstract][Full Text] [Related]
4. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
Day JM; Houston JB
Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
[No Abstract] [Full Text] [Related]
5. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
Allgayer H; Kruis W; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
[TBL] [Abstract][Full Text] [Related]
7. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
Taggart AJ; McDermott BJ; Roberts SD
Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
[TBL] [Abstract][Full Text] [Related]
8. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
[TBL] [Abstract][Full Text] [Related]
9. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
[TBL] [Abstract][Full Text] [Related]
10. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
Dull BJ; Salata K; Goldman P
Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
[No Abstract] [Full Text] [Related]
11. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
Das KM; Eastwood MA
Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
[TBL] [Abstract][Full Text] [Related]
12. Interaction of omeprazole with enteric-coated salicylate tablets.
Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
[TBL] [Abstract][Full Text] [Related]
13. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
Eitner K; Hippius M; Reinicke C
Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
Klotz U; Maier K; Fischer C; Heinkel K
N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of enteric-coated penicillamine tablets.
Chambliss WG; Chambliss DA; Cleary RW; Jones AB; Harland EC; Kibbe AH
J Pharm Sci; 1984 Sep; 73(9):1215-9. PubMed ID: 6333505
[TBL] [Abstract][Full Text] [Related]
16. Absorption of enteric and non-enteric coated prednisolone tablets.
Hulme B; James VH; Rault R
Br J Clin Pharmacol; 1975 Aug; 2(4):317-20. PubMed ID: 1233990
[TBL] [Abstract][Full Text] [Related]
17. History of enteric coated sulfasalazine in rheumatoid arthritis.
Pinals RS
J Rheumatol Suppl; 1988 Sep; 16():1-4. PubMed ID: 2903922
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
Corey AE; Rose GM; Conklin JD
J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the absorption from some commercial enteric-release theophylline products.
Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
[TBL] [Abstract][Full Text] [Related]
20. Enteric coated quinidine compared to sustained release preparations during repeated administration.
Bakke OM; Aanderud L; Aslaksen A
Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
